New nanoparticle drug shows promise in early cancer trial
NCT ID NCT04640480
First seen Jan 28, 2026 · Last updated Jun 08, 2026 · Updated 23 times
Summary
This early-phase study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle form of a chemotherapy agent, given by IV, to see if it is safe and how the body processes it. The goal was to find the best dose and understand side effects, not to cure the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CHA Medical Center
Seongnam-si, Gyeonggi-do, 13496, South Korea
-
The Catholic University of Korea Seoul ST. Mary's Hospital
Seoul, Seoul, 06591, South Korea
-
The Severance Hospital of the Yonsei University
Seoul, Seoul, 03722, South Korea
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.